EVO
NASDAQ
$1.98
Evotec SE (EVO)
Evotec SE is a prominent global biotechnology company headquartered in Hamburg, Germany, specializing in delivering comprehensive drug discovery and development solutions to the pharmaceutical and biotech industries. The firm is distinguished by its collaborative strategy, forming partnerships with leading pharmaceutical entities and prestigious academic institutions to accelerate the progress of a diverse range of therapeutic programs, including small molecules, biologics, and cell therapies. With a strong and growing pipeline, Evotec is strategically positioned to leverage new opportunities within the biopharmaceutical sector, reaffirming its essential contribution to healthcare innovation and improved patient outcomes.
Sector:
Healthcare
Buy
Target: $3.80 (+91.92%)
Market Cap
$714M
P/B Ratio
0.95
Free Cash Flow Yield
-7.30%
Beta (5Y)
0.95
Price Chart
Valuation
Market Cap$714M
Forward P/E53.48
PEG1.42
P/S0.94
P/B0.95
Profitability
Total Revenue (TTM)$864M
Gross Profit (TTM)$92M
EBITDA-$137M
Profit Margin-77.8%
Operating Margin-35.4%
EPS-$0.59
Financial Health
Debt-to-Equity55.4%
Free Cash Flow Yield-7.30%
Growth & Risk
Revenue 5Y CAGR+7.68%
FCF 5Y CAGR-14.61%
Beta (5Y)0.95
Sharpe Ratio-1.13